Invesco Exchange-Traded Fund Trust - Invesco Pharmaceuticals ETF Past Earnings Performance
Past criteria checks 0/6
Invesco Exchange-Traded Fund Trust - Invesco Pharmaceuticals ETF's earnings have been declining at an average annual rate of -7.6%, while the Capital Markets industry saw earnings growing at 9.7% annually. Revenues have been declining at an average rate of 10.5% per year.
Key information
-7.6%
Earnings growth rate
-7.0%
EPS growth rate
| Capital Markets Industry Growth | 10.3% |
| Revenue growth rate | -10.5% |
| Return on equity | -10.1% |
| Net Margin | -537.7% |
| Last Earnings Update | 31 Oct 2023 |
Recent past performance updates
No updates
Recent updates
No updates
Revenue & Expenses BreakdownBeta
How Invesco Exchange-Traded Fund Trust - Invesco Pharmaceuticals ETF makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Oct 23 | 5 | -25 | 2 | 0 |
| 31 Jul 23 | 5 | -8 | 2 | 0 |
| 30 Apr 23 | 5 | 8 | 2 | 0 |
| 31 Jan 23 | 5 | 0 | 2 | 0 |
| 31 Oct 22 | 5 | -7 | 2 | 0 |
| 31 Jul 22 | 5 | -6 | 2 | 0 |
| 30 Apr 22 | 6 | -4 | 2 | 0 |
| 31 Jan 22 | 6 | 42 | 2 | 0 |
| 31 Oct 21 | 5 | 87 | 2 | 0 |
| 31 Jul 21 | 5 | 84 | 2 | 0 |
| 30 Apr 21 | 5 | 81 | 2 | 0 |
| 31 Jan 21 | 5 | 49 | 2 | 0 |
| 31 Oct 20 | 5 | 17 | 2 | 0 |
| 31 Jul 20 | 5 | 7 | 2 | 0 |
| 30 Apr 20 | 5 | -3 | 2 | 0 |
| 31 Jan 20 | 7 | -24 | 2 | 0 |
| 31 Oct 19 | 8 | -44 | 2 | 0 |
| 31 Jul 19 | 8 | -12 | 3 | 0 |
| 30 Apr 19 | 8 | 20 | 3 | 0 |
| 31 Jan 19 | 8 | 30 | 3 | 0 |
| 31 Oct 18 | 7 | 40 | 3 | 0 |
| 31 Jul 18 | 8 | 32 | 3 | 0 |
| 30 Apr 18 | 8 | 24 | 4 | 0 |
| 31 Jan 18 | 10 | 55 | 4 | 0 |
| 31 Oct 17 | 11 | 87 | 4 | 0 |
| 31 Jul 17 | 12 | 32 | 5 | 0 |
| 30 Apr 17 | 13 | -22 | 5 | 0 |
| 31 Jan 17 | 14 | -107 | 6 | 0 |
| 31 Oct 16 | 16 | -192 | 7 | 0 |
| 31 Jul 16 | 17 | -208 | 8 | 0 |
| 30 Apr 16 | 19 | -225 | 9 | 0 |
| 31 Jan 16 | 19 | -89 | 10 | 0 |
| 31 Oct 15 | 19 | 48 | 10 | 0 |
| 31 Jul 15 | 17 | 218 | 9 | 0 |
| 30 Apr 15 | 15 | 388 | 8 | 0 |
| 31 Jan 15 | 13 | 388 | 7 | 0 |
| 31 Oct 14 | 12 | 387 | 6 | 0 |
| 31 Jul 14 | 10 | 323 | 5 | 0 |
| 30 Apr 14 | 9 | 259 | 5 | 0 |
| 31 Jan 14 | 8 | 214 | 4 | 0 |
| 31 Oct 13 | 7 | 169 | 3 | 0 |
| 31 Jul 13 | 7 | 128 | 2 | 0 |
Quality Earnings: PJP is currently unprofitable.
Growing Profit Margin: PJP is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PJP is unprofitable, and losses have increased over the past 5 years at a rate of 7.6% per year.
Accelerating Growth: Unable to compare PJP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PJP is unprofitable, making it difficult to compare its past year earnings growth to the Capital Markets industry (3.3%).
Return on Equity
High ROE: PJP has a negative Return on Equity (-10.15%), as it is currently unprofitable.